WALTHAM, Mass., June 14, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the
“Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and
disorders of the eye, announced today the completion of its previously announced public offering of 5,336,667 shares of the
Company’s common stock, 1,995 shares of Series B Convertible Preferred Stock (convertible into 1,330,000 shares of common stock)
and warrants to purchase 6,666,667 shares of common stock for aggregate gross proceeds of $10.0 million.
The offering was priced at $1.50 per share of common stock (or common stock equivalent), with each share of common stock (or
common stock equivalent) sold with one five-year warrant to purchase one share of common stock, at an exercise price of $1.50 per
share.
The Company intends to use the net proceeds of the offering to support its operations, including for clinical trials, for
working capital and for other general corporate purposes, which will include the pursuit of the Company’s other research and
development efforts and could also include the acquisition or in-license of other products, product candidates or technologies
candidates or technologies.
Rodman & Renshaw, a unit of H.C. Wainwright & Co., acted as exclusive placement agent for the offering.
The securities were offered and sold pursuant to a registration statement on Form S-1 (File No. 333-217418) previously filed
with the Securities and Exchange Commission (the "SEC") and declared effective on June 8, 2017 and a related registration statement
that was filed pursuant to Rule 462 promulgated under the Securities Act of 1933 to register additional securities. The
securities may only be offered only by means of a prospectus. The final prospectus related to the offering was filed with the SEC
on June 12, 2017. Copies of the final prospectus may be obtained at the SEC's website located at http://www.sec.gov, and may also be obtained from H.C. Wainwright & Co., LLC by calling (646)
975-6996 or emailing placements@hcwco.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor may there be any sale of
these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.
About EyeGate:
EyeGate is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products for
treating diseases and disorders of the eye. EyeGate is developing products using CMHA-S, a modified form of the natural polymer
hyaluronic acid (HA), which possesses unique physical and chemical properties such as hydration and healing properties. The ability
of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for
treating various ocular surface injuries.
EGP-437, EyeGate’s other product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone
Phosphate that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate II
Delivery System. For more information, please visit www.EyeGatePharma.com.
Forward-looking Statements
Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the
Private Securities Litigation Reform Act of 1995. These “forward-looking” statements include statements relating to, among other
things, the commercialization efforts and other regulatory or marketing approval efforts pertaining to EyeGate’s products,
including EyeGate’s EGP-437 combination product and those of Jade, a wholly owned subsidiary of EyeGate, as well as the success
thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks
and uncertainties that may cause results to differ materially from the statements set forth in this press release, plus other risk
factors described under the heading “Risk Factors” contained in our Annual Report on Form 10-K filed with the SEC on February 23,
2017 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The
forward-looking statements in this press release speak only as of the date of this press release. EyeGate expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations
with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.
Contact: Lee Roth / Janhavi Mohite The Ruth Group for EyeGate Pharmaceuticals 646-536-7012 / 7026 lroth@theruthgroup.com / jmohite@theruthgroup.com
